DRMA
Dermata Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-37/100
Last price
1.13
▲ 0.02 (1.80%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.11
Day high
1.14
Day low
1.11
Volume
29.58K
Market cap
$5.60M
P/E (TTM)
—
52W range
0.95 – 5.18
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
-6.61%
-7.8%
3M
-19.29%
-23.8%
6M
-16.30%
-34.5%
YTD
-51.29%
-65.5%
1Y
-76.75%
-93.2%
3Y
-99.29%
-181.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DRMA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+272.10K
Net buying
Buy transactions
2
272.11K shares
Sell transactions
1
11 shares
Net transactions
+3
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
1.10M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | PROEHL GERALD T Chief Executive Officer |
STOCK | 170.07K | $0 | Indirect |
| Aug 14, 26 | VAN HOOSE KYRI K Chief Financial Officer |
STOCK | 102.04K | $0 | Direct |
| Jun 16, 26 | SCOTT KATHLEEN D Director |
SELL | 11 | $13 | Direct |
| Feb 17, 26 | BEDOYA-TORO MUNERA MARIA E Officer |
BUY | 1.00K | $1.27K | Direct |
| Dec 23, 25 | PROEHL GERALD T Chief Executive Officer |
STOCK | 612.75K | $0 | Indirect |
| Dec 23, 25 | VAN HOOSE KYRI K Chief Financial Officer |
STOCK | 122.55K | $0 | Direct |
| Jan 23, 25 | HALE DAVID F Director |
STOCK | 78.74K | $0 | Indirect |
| Jan 21, 25 | FISHER MARY Director |
STOCK | 196.85K | $0 | Direct |
| Jan 21, 25 | VAN HOOSE KYRI K Chief Financial Officer |
STOCK | 78.74K | $0 | Direct |
| Jan 21, 25 | PROEHL GERALD T Chief Executive Officer |
STOCK | 787.40K | $0 | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEDOYA-TORO MUNERA MARIA E |
Officer | 1.05K | Purchase |
FISHER MARY |
Director | 196.95K | Stock Award(Grant) |
HALE DAVID F |
Director | — | Stock Award(Grant) |
PROEHL GERALD T |
Chief Executive Officer | — | Stock Award(Grant) |
SCOTT KATHLEEN D |
Director | 1 | Sale |
VAN HOOSE KYRI K |
Chief Financial Officer | 232.46K | Stock Award(Grant) |
Fundamentals
Market cap$5.60M
Enterprise value$132.26K
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-8.37M
EPS (TTM)$-4.39
Free cash flow$-5.11M
Total cash$4.41M
Total debt$0
Book value / share$0.87
Shares outstanding4.96M
Float2.90M
Short % of float2.94%
Dividend yield0.00%
Beta (5Y)0.66
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.29
PEG ratio—
Price / sales—
Price / book1.30
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-183.89%
Return on assets-89.88%
Debt / equity—
Current ratio2.81
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $2.93M | $8.20M | $4.07M | $5.65M | -64.3% |
| Selling, general & admin | $4.84M | $4.31M | $3.97M | $4.02M | +12.4% |
| Total operating expense | $7.77M | $12.51M | $8.04M | $9.67M | -37.9% |
| Operating income | -$7.77M | -$12.51M | -$8.04M | -$9.67M | +37.9% |
| Net interest income | $215.04K | $225.78K | $247.22K | $63.57K | -4.8% |
| Pre-tax income | -$7.56M | -$12.29M | -$7.79M | -$9.61M | +38.5% |
| Net income | -$7.56M | -$12.29M | -$7.79M | -$9.61M | +38.5% |
| Net income to common | -$7.56M | -$12.29M | -$7.79M | -$9.61M | +38.5% |
| Basic EPS | -8.16 | -80.32 | -399.90 | -2,088.00 | +89.8% |
| Diluted EPS | -8.16 | -80.32 | -399.90 | -2,088.00 | +89.8% |
| EBIT | -$7.77M | -$12.51M | -$8.04M | -$9.67M | +37.9% |
| EBITDA | -$7.77M | -$12.51M | -$8.04M | -$9.67M | +37.9% |
| Basic shares | 926.19K | 152.97K | 19.49K | 4.60K | +505.5% |
| Diluted shares | 926.19K | 152.97K | 19.49K | 4.60K | +505.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.52M | $3.16M | $7.44M | $6.24M | +137.9% |
| Cash & short-term investments | $7.52M | $3.16M | $7.44M | $6.24M | +137.9% |
| Total current assets | $7.86M | $3.53M | $7.98M | $6.94M | +122.5% |
| Total assets | $7.86M | $3.53M | $7.98M | $6.94M | +122.5% |
| Total current liabilities | $1.64M | $1.97M | $1.62M | $922.63K | -16.8% |
| Total liabilities | $1.64M | $1.97M | $1.62M | $922.63K | -16.8% |
| Retained earnings | -$73.23M | -$65.68M | -$53.39M | -$45.59M | -11.5% |
| Shareholder equity | $6.22M | $1.56M | $6.36M | $6.02M | +298.7% |
| Working capital | $6.22M | $1.56M | $6.36M | $6.02M | +298.7% |
| Net tangible assets | $6.22M | $1.56M | $6.36M | $6.02M | +298.7% |
| Shares issued | 2.66M | 251.78K | 26.20K | 5.13K | +956.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.56M | -$12.29M | -$7.79M | -$9.61M | — | +38.5% |
| Depreciation & amortisation | — | — | — | — | $0 | — |
| Stock-based compensation | $143.73K | $657.65K | $522.08K | $930.33K | — | -78.1% |
| Change in working capital | -$342.73K | $466.86K | $863.68K | -$153.58K | — | -173.4% |
| Operating cash flow | -$7.76M | -$11.16M | -$6.41M | -$8.83M | — | +30.5% |
| Share buybacks | -$367 | -$828 | -$40 | $0 | — | +55.7% |
| Financing cash flow | $12.12M | $6.89M | $7.61M | $4.28M | — | +76.0% |
| Free cash flow | -$7.76M | -$11.16M | -$6.41M | -$8.83M | — | +30.5% |
| End cash position | $7.52M | $3.16M | $7.44M | $6.24M | — | +137.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $212.56K | $383.72K | $526.62K | $504.39K | $617.84K | — | -44.6% |
| Selling, general & admin | $2.80M | $1.54M | $1.37M | $1.26M | $1.15M | — | +81.6% |
| Total operating expense | $3.01M | $1.93M | $1.90M | $1.76M | $1.77M | — | +56.4% |
| Operating income | -$3.01M | -$1.93M | -$1.90M | -$1.76M | -$1.77M | — | -56.4% |
| Net interest income | $46.50K | $78.68K | $38.51K | $68.68K | $71.64K | — | -40.9% |
| Pre-tax income | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | — | -60.6% |
| Net income | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | — | -60.6% |
| Net income to common | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | — | -60.6% |
| Basic EPS | -0.74 | -0.48 | — | -1.65 | -1.66 | -4.47 | -54.2% |
| Diluted EPS | -0.74 | -0.48 | — | -1.65 | -1.66 | -4.47 | -54.2% |
| EBIT | -$3.01M | -$1.93M | -$1.90M | -$1.76M | -$1.77M | — | -56.4% |
| EBITDA | -$3.01M | -$1.93M | -$1.90M | -$1.76M | -$1.77M | — | -56.4% |
| Basic shares | 4.02M | 3.86M | — | 1.03M | 1.03M | 515.47K | +4.2% |
| Diluted shares | 4.02M | 3.86M | — | 1.03M | 1.03M | 515.47K | +4.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | -36.5% |
| Cash & short-term investments | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | -36.5% |
| Inventory | $149.73K | $93.09K | — | — | — | +60.8% |
| Total current assets | $5.16M | $7.47M | $7.86M | $5.07M | $6.64M | -30.9% |
| Property, plant & equipment | $129.37K | — | — | — | — | — |
| Total assets | $5.32M | $7.47M | $7.86M | $5.07M | $6.64M | -28.7% |
| Total current liabilities | $1.83M | $1.05M | $1.64M | $1.11M | $1.03M | +74.1% |
| Total liabilities | $1.83M | $1.05M | $1.64M | $1.11M | $1.03M | +74.1% |
| Retained earnings | -$78.05M | -$75.08M | -$73.23M | -$71.37M | -$69.68M | -4.0% |
| Shareholder equity | $3.49M | $6.41M | $6.22M | $3.96M | $5.61M | -45.6% |
| Working capital | $3.32M | $6.41M | $6.22M | $3.96M | $5.61M | -48.2% |
| Net tangible assets | $3.49M | $6.41M | $6.22M | $3.96M | $5.61M | -45.6% |
| Shares issued | 4.02M | 4.02M | 2.66M | 844.46K | 637.76K | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | -60.6% |
| Stock-based compensation | $41.78K | $43.28K | $29.47K | $37.84K | $39.23K | -3.5% |
| Change in working capital | $503.75K | -$675.29K | $503.22K | -$149.67K | -$1.03M | +174.6% |
| Operating cash flow | -$2.42M | -$2.48M | -$1.33M | -$1.80M | -$2.69M | +2.3% |
| Share buybacks | — | — | $0 | -$367 | — | — |
| Financing cash flow | -$323 | $1.90M | $4.19M | -$12.99K | -$547.86K | -100.0% |
| Free cash flow | -$2.53M | -$2.48M | -$1.33M | -$1.80M | -$2.69M | -2.1% |
| End cash position | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | -36.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.55 | -0.74 | -34.6% |
| Mar 2026 | -0.53 | -0.48 | +9.4% |
| Dec 2025 | -1.54 | -1.52 | +1.3% |
| Sep 2025 | -1.59 | -1.65 | -3.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.55 | 1 | $25.00K | 0.0% |
| Next quarter | -0.46 | 1 | $75.00K | 0.0% |
| Current year | -2.17 | 1 | $100.00K | 0.0% |
| Next year | -1.43 | 1 | $750.00K | +650.0% |
Analyst targets & ownership
Mean target$4.00
High target$4.00
Low target$4.00
Implied upside253.98%
Analyst count1
ConsensusNONE
Strong buy / Buy1 / 0
Hold0
Sell / Strong sell0 / 0
Held by insiders27.35%
Held by institutions7.77%
Institutions holding16
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.12
+0.58% from price
SMA 20
1.14
-1.25% from price
SMA 50
1.25
-9.30% from price
SMA 100
1.26
-10.21% from price
SMA 200
1.43
-21.01% from price
EMA 12
1.13
-0.25% from price
EMA 26
1.18
-4.05% from price
EMA 50
1.22
-7.49% from price
RSI (14)
43.1
Neutral
MACD (12,26,9)
-0.04
Hist 0.00
ATR (14)
0.06
5.53% of price
Realised vol 30D
52.1%
Annualised
Bollinger upper
1.21
20, 2σ
Bollinger lower
1.08
20, 2σ
50 / 200 cross
Death
1.25 vs 1.43
Trend bias
Below 200
-21.01%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.12
More volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
52.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-80.0%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.06
5.53% of price
Beta (reported)
0.66
5Y monthly, from filing
Short interest
Shares short
120.02K
Prior 366.82K
Change vs prior
-67.3%
Shorts covering
% of float
2.94%
Normal
% of shares out
2.42%
Against total outstanding
Days to cover
1.3
Liquid
Float
2.90M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| May 21, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| Aug 21, 24 | Maxim Group | MAINTAINED | Buy | Buy |
| Mar 23, 23 | Maxim Group | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateAug 1, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-17
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-08-05
Offering Registrations
S-8 · 2026-06-04
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-27
Offering Registrations
S-3/A · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-17
Headlines
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
GlobeNewswire · 37d ago
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
ACCESS Newswire · 43d ago
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
ACCESS Newswire · 47d ago
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
ACCESS Newswire · 51d ago
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
ACCESS Newswire · 57d ago
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
ACCESS Newswire · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.